Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study
tASCT provides clinical benefit for MRD-positive MM patients, particularly those achieving significant MRD reduction. These findings support tASCT as a feasible approach for MRD-positive patients following initial ASCT.
Authors
- Seung‐Ah Yahng (ORCID: https://orcid.org/0000-0002-3044-3991)
- Young‐Woo Jeon (ORCID: https://orcid.org/0000-0003-3362-8200)
- Myungshin Kim (ORCID: https://orcid.org/0000-0001-8632-0168)
- Si-Eun Oh (ORCID: https://orcid.org/0009-0009-9584-6060)
- Jae‐Ho Yoon (ORCID: https://orcid.org/0000-0002-2145-9131)
- Sung‐Soo Park (ORCID: https://orcid.org/0000-0002-8826-4136)
- Jin Hwa Jung (ORCID: https://orcid.org/0000-0001-5280-5554)
- Hee‐Je Kim (ORCID: https://orcid.org/0000-0003-4098-3366)
- Chang‐Ki Min (ORCID: https://orcid.org/0000-0002-1940-0392)
- Jung Yeon Lee (ORCID: https://orcid.org/0009-0005-9052-5912)
- Seung-Hwan Shin
- Sung-Eun Lee
- Andrew C. Ahn
Institutions
- St. Mary's Hospital (US)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
- St. Mary's Hospital (US)
- St. Paul's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Blood Research
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1007/s44313-025-00101-6
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Food and Drug Safety